Navigating Challenges in Pharma Supply Chain: Insights and Strategies
Dear Readers, welcome to this monographic issue focused on Pharma Supply Chain. In
Dear Readers, welcome to this monographic issue focused on Pharma Supply Chain. In
Building on his recent talk at Amplexor (ArisGlobal)’s annual global BE THE EXPERT conference, Steve Gens of Gens & Associates reports the top-level findings of a far-reaching new regulatory study into the evolving role and challenges at a regional and country level. Improving local Affiliate effectiveness is critical for a true end-to-end global regulatory information management capability.
It would be easy to conclude that the implementation of IDMP standards for future regulatory exchanges is the be-all and end-all of pharma regulatory process modernisation and the only driver of current IT and data-based projects. Yet the significantly updated eCTD 4.0 standard, whose details have now been published, is at least just as important, affecting the way Life Sciences companies submit dossiers internationally. Amplexor’s Agnes Cwienczek summarises the key requirements and the preparations now needed.
Biocides are important tools for society to maintain its standards of health and to achieve its targets for a sustainable future. The benefits that biocides offer to meet these goals are balanced by the need to ensure they can be used safely. The Biocidal Product Regulation (BPR) controls the use of biocides and it has been in force now for 10 years. The BPR is arguably the most complex piece of legislation regulating the use of chemicals in Europe. Its complexity is compounded by delays in delivering its core purpose. This article looks at some of the changes to the BPR over the last 10 years, it considers progress made in delivering key regulatory objectives and offers some thoughts on how the BPR might evolve in the future.
How does Sinocompound ensure that customers can access the best-performing catalysts and ligands,
How does Grifols Partnership ensure successful project completion when working with small and emerging
Can you describe better PROCOS’ new investments? In a continuous evolving world, PROCOS focused
IBSA is a regular presence at the Cphi events. After Tokyo, you will be
Addressing some of the challenges in a transition to the circular bioeconomy, this paper first explores the use of next generation processing approaches to help move pharmaceutical, chemical, and biomaterial products from fossil carbon to its biobased alternative. It posits the use of system-oriented cluster technologies through the application of cluster governance to increase both collaboration and knowledge exchange and to help facilitate the transition to a circular bioeconomy in a fast and effective manner.
The concept of multi-catalysis is an emerging field targeting the development of new efficient catalytic systems combining multi-step synthesis in new ‘one-pot’ transformations or in multi-catalytic sequences. In this article, we will review the main classification of multi-catalysis strategies and illustrating some case-studies which combine different catalysis fields leading to some remarkable opportunities to outcompete classical approaches. Despite major challenges that need to be addressed with respect to compatibility issues and catalyst reactivity ordering, the implementation of such processes enables to strengthen the collaboration across many disciplines enhancing interdisciplinary competences.